Physician profile
Vikrant S Brar
NPI 1346447729
$1,275.56
in general payments reported to CMS, 2019-2025
25 companies · $62.17 in 2025
The $62.17 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $430 · 2021: $32.42 · 2022: $77.40 · 2023: $345 · 2024: $143 · 2025: $62.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $299 · Food and Beverage: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $299.10 |
| Food and Beverage | $250.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $357.14 | 2019-2023 | |
| Genentech, INC. | $120.38 | 2024 | Itovebi |
| Daiichi Sankyo INC. | $91.47 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $90.66 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $77.25 | 2020-2022 | |
| Amgen INC. | $62.64 | 2019-2022 | |
| Genentech USA, INC. | $51.32 | 2019-2020 | |
| Karyopharm Therapeutics INC. | $38.67 | 2020 | |
| Caris Mpi, INC. | $36.02 | 2025 | Mi Cancer Seek |
| Puma Biotechnology, INC. | $32.04 | 2020 | |
| Seagen INC. | $29.57 | 2020 | |
| Foundation Medicine, INC. | $28.31 | 2019 | |
| Lilly USA, LLC | $28.05 | 2019 | |
| Glaxosmithkline, LLC. | $26.61 | 2020 | |
| Novocure INC. | $26.15 | 2025 | Optune Lua (Novottf-200t) |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $25.15 | 2020 | |
| Janssen Scientific Affairs, LLC | $22.44 | 2024 | Darzalex, Tecvayli |
| Merck Sharp & Dohme LLC | $21.00 | 2020 | |
| Pharmacosmos Therapeutics INC. | $20.69 | 2023 | Monoferric |
| Global Blood Therapeutics, INC. | $17.88 | 2021 | |
| Genzyme Corporation | $17.22 | 2020 | |
| Taiho Oncology, INC. | $15.75 | 2020 | |
| Astellas Pharma US INC | $14.82 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.26 | 2020 | |
| Clovis Oncology, INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikrant Brar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.